FXa inhibition and coagulation changes during DVT prophylaxis by enoxaparin over the course of a 15-day follow-up in septic patients

Clinical and Applied Thrombosis/Hemostasis

Volumn 16, Issue 5, 2010, Pages 584-590

  Zenáhlíková, Zuzana ^a   Kvasnička, Jan ^a   Kudrnová, Zuzana ^a   Sudrová, Magda ^a   Brzežková, Radka ^a   Mazoch, Jiří ^a   Malíková, Ivana ^a   Výborný, Josef ^a   Erhart, David ^b   Pecen, Ladislav ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CENTRAL MILITARY HOSPITAL   (Czech Republic)

Author keywords

Hemostasis; Intensive care unit; Low molecular weight heparin; Sepsis; Venous thromboembolism

Indexed keywords

ALPHA 1 ANTITRYPSIN; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A; C REACTIVE PROTEIN; D DIMER; ENOXAPARIN; FIBRINOGEN; INTERLEUKIN 6; OROSOMUCOID; PROTEIN C;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FOLLOW UP; HEMOSTASIS; HUMAN; INTENSIVE CARE UNIT; MALE; PARTIAL THROMBOPLASTIN TIME; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTHROMBIN TIME; SEPSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BLOOD COAGULATION; ENOXAPARIN; FACTOR XA; HUMANS; MALE; MIDDLE AGED; SEPSIS; VENOUS THROMBOSIS;

EID: 77955874392     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029609345686     Document Type: Article

References (30)

1. Levi M., ten Cate H., van der Poll T. Endothelium: interface between coagulation and inflammation. Crit Care Med. 2002 ; 30 (5 suppl). S220 - S224.
2. Esmon CT, Fukudome K., Mather T., et al. Inflammation, sepsis, and coagulation. Haematologica. 1999 ; 84 (3). 254-259.
3. Samama MM An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med. 2000 ; 160 (22). 3415-3420.
4. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008 ; 36 (1). 296-327.
5. Dorffler-Melly J., de Jonge E., Pont AC, et al. Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors. Lancet. 2002 ; 359 (9309). 849-850.
6. Jochberger S., Mayr V., Luckner G., et al. Antifactor Xa activity in critically ill patients receiving antithrombotic prophylaxis with standard dosages of certoparin: a prospective, clinical study. Crit Care. 2005 ; 9 (5). R541 - R548.
7. Priglinger U., Delle Karth G., Geppert A., et al. Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill? Crit Care Med. 2003 ; 31 (5). 1405-1409.
8. Rommers MK, Van der Lely N., Egberts TC, van den Bemt PM Anti-Xa activity after subcutaneous administration of dalteparin in ICU patients with and without subcutaneous oedema: a pilot study. Crit Care. 2006 ; 10 (3). R93.
9. Rutherford EJ, Schooler WG, Sredzienski E., Abrams JE, Skeete DA Optimal dose of enoxaparin in critically ill trauma and surgical patients. J Trauma. 2005 ; 58 (6). 1167-1170.
10. De Paepe P., Belpaire FM, Buylaert WA Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock. Clin Pharmacokinet. 2002 ; 41 (14). 1135.
11. Rabbat CG, Cook DJ, Crowther MA, et al. Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency. J Crit Care. 2005 ; 20 (4). 357-363.
12. Duhl AJ, Paidas MJ, Ural SH, et al, for the Pregnancy and Thrombosis Working Group. Antithrombotic therapy and pregnancy: consensus report and recommendations for prevention and treatment of venous thromboembolism and adverse pregnancy outcomes. Am J Obstet Gynecol. 2007 ; 197 (5). 457.e1-457.e21.
13. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 1999 ; 341 (11). 793-800.
14. Gruys E., Toussaint MJ, Niewold TA, Koopmans SJ Acute phase reaction and acute phase proteins. J Zhejiang Univ Sci B. 2005 ; 6 (11). 1045-1056.
15. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003 ; 31 (4). 1250-1256.
16. Dellinger RP, Carlet JM, Masur H., et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med. 2004 ; 32 (3). 858-873.
17. Knaus WA, Draper EA, Wagner DP, Zimmerman JE Apache II: a severity of disease classification system. Crit Care Med. 1985 ; 13 (10). 818-829.
18. Clark LC, Thompson HL Determination of creatine and creatinine in urine. Anal Chem. 1949 ; 21 (10). 1218-1221.
19. Bland JM, Altman DG Correlation, regression, and repeated data. BMJ. 1994 ; 308 (6933). 896.
20. Bland JM, Altman DG Calculating correlation coefficients with repeated observations: part 1-correlation within subjects. BMJ. 1995 ; 310 (6977). 446.
21. Taylor FB Jr, Toh CH, Hoots WK, Wada H., Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001 ; 86 (5). 1327-1330.
22. Hirsh J., Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 ; 126 (3 suppl). 188S - 203S.
23. Xiao H., Siddiqui J., Remick DG Mechanisms of mortality in early and late sepsis. Infect Immun. 2006 ; 74 (9). 5227-5235.
24. Kinasewitz GT, Yan SB, Basson B., et al. Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569]. Crit Care. 2004 ; 8 (2). R82 - R90.
25. Biolo G., Toigo G., Ciocchi B., et al. Metabolic response to injury and sepsis: changes in protein metabolism. Nutrition. 1997 ; 13 (9 suppl). 52S - 57S.
26. Briza J., Kudrna K., Kvasnicka J., Busta O., Trca T. Acute phase reaction in severe injuries [in Czech]. Sb Lek. 2002 ; 103 (2). 193-202.
27. Young E., Prins M., Levine MN, Hirsh J. Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemost. 1992 ; 67 (6). 639-643.
28. Desjardins L., Bara L., Boutitie F., et al. Correlation of plasma coagulation parameters with thromboprophylaxis, patient characteristics, and outcome in the MEDENOX study. Arch Pathol Lab Med. 2004 ; 128 (5). 519-526.
29. Freedman MD A bioavailability study in the proposed patient population-with much more needed now. Crit Care Med. 2003 ; 31 (5). 1588-1589.
30. Levine MN, Planes A., Hirsh J., Goodyear M., Vochelle N., Gent M. The relationship between anti-factor Xa level and clinical outcome in patients receiving enoxaparine low molecular weight heparin to prevent deep vein thrombosis after hip replacement. Thromb Haemost. 1989 ; 62 (3). 940-944.